Trade Report: Today, Nivalis Therapeutics Inc. (NVLS) Rating Decreased to Hold at Stifel Nicolaus

Today, Nivalis Therapeutics Inc. (NVLS) Rating Decreased to Hold at Stifel Nicolaus

Nivalis Therapeutics Inc. (NASDAQ:NVLS) was downgraded by equities researchers at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report issued on Tuesday. They presently have a $3.25 price target on the stock, down from their prior price target of $16.00. Stifel Nicolaus’ price target suggests a potential downside of 48.00% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut Nivalis Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 8th. Raymond James Financial Inc. assumed coverage on Nivalis Therapeutics in a research note on Tuesday, September 13th. They issued an “outperform” rating and a $20.00 price target on the stock. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $16.00 price target on shares of Nivalis Therapeutics in a research note on Tuesday, August 30th. HC Wainwright reaffirmed a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 8th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 1st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $11.25.

Shares of Nivalis Therapeutics (NASDAQ:NVLS) opened at 6.25 on Tuesday. The stock’s 50 day moving average price is $6.46 and its 200-day moving average price is $5.84. Nivalis Therapeutics has a 1-year low of $3.68 and a 1-year high of $9.45. The company’s market capitalization is $97.14 million.

Nivalis Therapeutics (NASDAQ:NVLS) last announced its earnings results on Monday, November 7th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. On average, equities analysts predict that Nivalis Therapeutics will post ($2.10) EPS for the current year.

In other news, EVP David Malcom Rodman sold 5,820 shares of the stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total value of $46,327.20. Following the sale, the executive vice president now directly owns 18,056 shares of the company’s stock, valued at $143,725.76. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.00% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in NVLS. BVF Inc. IL boosted its stake in Nivalis Therapeutics by 24.5% in the second quarter. BVF Inc. IL now owns 1,926,443 shares of the company’s stock valued at $8,862,000 after buying an additional 379,700 shares during the period. AXA boosted its stake in Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock valued at $2,455,000 after buying an additional 139,652 shares during the period. Opaleye Management Inc. boosted its stake in Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock valued at $1,287,000 after buying an additional 160,000 shares during the period. Sphera Funds Management LTD. purchased a new position in Nivalis Therapeutics during the third quarter worth $1,664,000. Finally, Endurant Capital Management LP increased its position in Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares in the last quarter. 79.26% of the stock is currently owned by institutional investors.

About Nivalis Therapeutics

Related posts

Leave a Comment